The introduction of targeted therapy and immunotherapy has produced significant survival improvement in adenocarcinoma, with the most pronounced benefits in immunotherapy. Treatment efficacy varies across subgroups highlighting the need for further investigation to optimize personalized therapy.
Ji et al. (2026) studied this question.